Top Interventional Oncology Companies

Skyquest Technology's expert advisors have carried out comprehensive research and identified these companies as industry leaders in the Interventional Oncology Market. This Analysis is based on comprehensive primary and secondary research on the corporate strategies, financial and operational performance, product portfolio, market share and brand analysis of all the leading Interventional Oncology industry players.

Interventional Oncology Market Competitive Landscape

The market's key players are undertaking various strategic initiatives such as the signing of a collaborations, new partnership agreement, mergers and acquisitions, geographic coverage, with the goal of strengthening their product portfolio and manufacturing capacities, thereby providing a competitive advantage. In 2021, Boston Scientific (US) led the worldwide interventional oncology market. To improve its market presence and product offerings, the corporation primarily relies on growth tactics such as acquisitions and expansions. The acquisition of BTG by the firm will help it increase its product portfolio in chemoembolization, radioembolization, and ablation treatments. Boston Scientific works hard to get regulatory and reimbursement approvals. As part of its long-term growth plan, the firm invests in both fast-growing and new areas in order to improve its position in the global healthcare sector.

Interventional Oncology Market Top Player's Company Profiles

  • Medtronic (Ireland)
  • Teleflex (US)
  • Boston Scientific Corporation
  • BTG International Ltd. (acquired by Boston Scientific)
  • Cook Medical Inc.
  • AngioDynamics Inc.
  • Terumo Corporation
  • Merit Medical Systems Inc.
  • Johnson & Johnson Services Inc.
  • MedWaves, Inc.
  • Healthtronics Inc.
  • Trod Medical
  • InSightec Ltd.
  • Sirtex Medical Limited
  • Sanarus Technologies, LLC
  • C.R. Bard, Inc. (acquired by Becton, Dickinson and Company)
  • Guerbet Group
  • Varian Medical Systems, Inc.
  • Nanobiotix SA
  • OncoTherapy Science, Inc.

Interventional Oncology Market Recent Development

  • In September 2022, Philips announces significant development milestones for the world's first spectral detector Angio CT system. Leiden University Medical Centre has joined a global network of partners in the development of the Philips Spectral Angio CT suite and its application in clinical research, bringing spectral CT imaging technology into an integrated hybrid Angio CT suite with the goal of innovating a variety of treatment procedures.
  • In September 2022, Merit Medical Systems, Inc. a global manufacturer and marketer of healthcare equipment, has announced the commercial launch of the Prelude Roadster Guide Sheath in the United States. The Merit Vascular-Peripheral Access portfolio now includes the Prelude Roadster, in addition to introducers and other devices such as access kits, vascular dilators, and accessories.
  • In September 2022, Aster Hospitals Bengaluru, a subsidiary of Aster DM Healthcare, has established the Aster International Institute of Oncology (AIIO). This newly established institute will serve as a centre of excellence for the treatment of all malignancies under one roof.

REQUEST FOR SAMPLE

Want to customize this report? REQUEST FREE CUSTOMIZATION

FAQs

Global Interventional Oncology Market size was valued at USD 2.31 Billion in 2024 and is poised to grow from USD 2.47 Billion in 2025 to USD 4.18 Billion by 2033, growing at a CAGR of 6.8% during the forecast period (2026–2033).

The key vendors in the Interventional Oncology Market include Medtronic plc, Boston Scientific Corporation, Johnson & Johnson, Terumo Corporation, Merit Medical Systems, Inc., AngioDynamics, Inc., Stryker Corporation, Siemens Healthineers AG, GE HealthCare Technologies Inc., and Varian Medical Systems. These companies focus on advanced ablation technologies, embolization therapies, image-guided procedures, and minimally invasive cancer treatments.

The key driver of the Interventional Oncology Market is the rising global prevalence of cancer and growing demand for minimally invasive treatment options. Increasing adoption of image-guided ablation, embolization procedures, and targeted therapies, alongside technological advancements and shorter patient recovery times, further supports market growth.

The key market trend in the Interventional Oncology Market is the growing adoption of image-guided, minimally invasive cancer treatments. Advancements in robotic-assisted procedures, microwave ablation, radiofrequency ablation, and precision embolization technologies are improving treatment accuracy, reducing recovery times, and expanding options for patients with complex tumors.

North America accounted for the largest share of the Interventional Oncology Market, driven by advanced healthcare infrastructure, high cancer prevalence, and widespread adoption of minimally invasive procedures. Strong reimbursement frameworks, increasing investments in cancer treatment technologies, and the presence of leading medical device manufacturers further support regional market dominance.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Interventional Oncology Market
Interventional Oncology Market

Report ID: SQMIG35G2238

[email protected]
USA +1 351-333-4748

BUY NOW GET FREE SAMPLE